Global Carcinoembryonic Antigen Market Research Report: Information by Application (Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, and Others), End User (Hospitals and Clinics, Diagnostic Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025
Market Highlights
Carcinoembryogenic antigen (CEA) is a group of glycoproteins which are produced during the fetal developmental stages by gastrointestinal tissues. CEA is responsible for cell adhesion. Healthy adults do not have CEA concentrations. However, smoking and certain medical conditions such as colorectal cancer, breast cancer etc. can mark the presence of CEA in the body. Thus, CEA based diagnostic assays are used for the detection of such cancers and to check the treatment efficiency during the therapeutic period by a physician.
Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/772
In 2017, studies of the NCBI suggested that the global burden of colorectal cancer will increase by 60%, leading to 2.2 million new cancer cases and 1.1 million deaths by 2030. This will increase the colorectal cancer diagnostic demands, thereby propelling the market growth.
Increasing prevalence of cancer, rising healthcare expenditures, and developing diagnostic technologies will boost the global market during the forecast period. However, risk of infection and hematoma, lack of awareness and medical services in the developing countries will restrain the market growth during the assessment period.
Market Players
Some of key players profiled in the report are Lee BioSolutions, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated., Correlogic Systems, Inc, Genway Biotech, Inc., Abbott., RayBiotech, Inc., Abcam plc., Biocare Medical, LLC, and Biocare Medical, LLC.
Regional Analysis
The Americas account for the largest share in the carcinoembryogenic antigen market. The Americas mainly include countries like the U.S. and Canada. Increasing prevalence of cancer and high healthcare expenditures within the region will boost the market growth over the assessment period.
Europe is the second highest revenue generating region in the global carcinoembryogenic antigen market. Increasing prevalence of cancer, fast adoption of new technologies and presence of developed countries like Germany and U.K within the region will boost the market growth during the forecasted period.
On account of the developing medical infrastructure, rising healthcare expenditure, and increasing government initiatives, Asia Pacific region is expected to grow the fastest.
The Middle East & Africa is expected to grow slower than the global average. The Middle Eastern countries, for instance, UAE and Saudi Arabia dominates the market due to high income and the government support to improve public health.
Taste the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Carcinoembryogenic Antigen Market” Research Report – Forecast till 2023.
Segmentation
The global carcinoembryonic antigen market has been segmented on the basis of application, sampling, and end user.
Based on application, the market has been segmented into colorectal, pancreatic, breast, lung cancer, and others.
Based on sampling, the market has been segmented into antecubital, peritoneal, pleural, serebrospinal, and others.
Based on the end users, the market has been segmented into hospitals, diagnostic centers, research centers, and others.
Access Report Details @ https://www.marketresearchfuture.com/reports/carcinoembryonic-antigen-market-772
The report for Global market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Intended Audience
- Biotechnology companies
- Pharmaceutical companies
- Hospitals and clinics
- Diagnostic centers
- Academic institutes
- Government organizations
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact Us:
Market Research Future
Phone: +1 646 845 9312
Email: [email protected]
Global Carcinoembryonic Antigen Market Research Report: Information by Application (Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, and Others), End User (Hospitals and Clinics, Diagnostic Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025Global Carcinoembryonic Antigen Market Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making.
This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability.
It provides information on trends and developments, and focuses on Markets and materials, capacities and technologies, and on the changing structure of the Serotonin Supplements Market.Some of the key players operating for the global market analysis are Lee BioSolutions (US), F. Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics Incorporated (US), Genway Biotech, Inc. (US), RayBiotech, Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Boster Biological Technology (US), Creative Diagnostics (US), and Laboratory Corporation of America Holdings (US)Carcinoembryonic Antigen Market Research Coverage:Changing market dynamics of the industryTo get a comprehensive overview of the Carcinoembryonic Antigen Market.Historical, current and projected market size in terms of volume and valueIn-depth market segmentationCompetitive landscapeThe report presents an all-inclusive database in a systematic and highly comprehensive manner.
It intends to offer valid, factual, reliable, and easily understandable information about the which makes it more eloquent.
Our analysis team applies a tried and tested primary and secondary research methodology to provide accurate and indubitable findings.Global Carcinoembryonic Antigen Market, by ApplicationColorectal CancerPancreatic CancerBreast CancerLung CancerOthersGlobal Carcinoembryonic Antigen Market, by End UserHospitals and ClinicsDiagnostic CentersOthersAccess Complete Detailed TOC Research Report at https://www.marketresearchfuture.com/reports/carcinoembryonic-antigen-market-772This report focuses on the global Carcinoembryonic Antigen Market status, future forecast, growth opportunity, key market and key players.
The study objectives are to present the Carcinoembryonic Antigen Market development in United States, Europe and China.Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South AmericaAbout Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Global Carcinoembryonic Antigen Market – OverviewCarcinoembryonic Antigen or CEA is a kind of glycoprotein produced by cells of the gastrointestinal tract during foetal development which is involved in cell adhesion.
Similarly for smokers the level of CEA ranges about <5.0 ng/ml.
It is reported that the CEA based diagnostic assays are mostly used for the detection of colorectal cancer.Factors such as increasing awareness, technological advancements in the medical sector and proteomics, increasing prevalence of colorectal cancer, and lifestyle changes involving the consumption of junk foods, alcohol, and others provides favourable backgrounds for the market growth.Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/772However, side effects related to the CEA test including unreasonable bleeding followed by blacking out, hematoma, risk of infection, erroneous readings and low healthcare expenditures in middle and low income countries is estimated to restrain the market growth during the forecast period.The global carcinoembryonic antigen market is expected to grow 6.7% during the forecast period.Global Carcinoembryonic Antigen Market - competitive AnalysisIn 2017, Aviva Systems Corporation (ASB), a protein solutions and application provider acquired GenWay Biotech, Inc. GenWay Biotech founded in 1998 has a multi-functional technology platform specialized in proteins and antibody solutions.
The Americas mainly include countries like the U.S. and Canada.
Avail the in-depth table of content (TOC) & market synopsis on “Global Carcinoembryogenic Antigen Market” Research Report – Forecast till 2023.Market PlayersSome of key players profiled in the report are Lee BioSolutions, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated., Correlogic Systems, Inc, Genway Biotech, Inc., Abbott., RayBiotech, Inc., Abcam plc., Biocare Medical, LLC, and Biocare Medical, LLC.TABLE OF CONTENTS REPORT PROLOGUE MARKET INTRODUCTION 2.1.
Opportunities MARKET FACTOR ANALYSIS 5.1.
The global Carcinoembryonic Antigen (CEA) market is expected to reach USD 2.56 Billion by 2022, which is anticipated to grow at a CAGR of more than 6.6% during the forecast period.
The market is expected to witness significant growth in the coming few years owing to various key attributes such as growing incidence of cancer and technological advancement regarding the development of novel biomarkers.
Furthermore, increased consumption of alcohol, less physical activity, unhealthy diet, and rapidly changing lifestyle also contribute in the growth of colorectal cancer in the recent years.Breast cancer is another segment experiencing significant growth owing to the factors such as rising female population above 50 years, advancements in biomarkers and increase in number of patients undertaking hormone replacement therapy (HRT), and breast augmentation & reconstruction surgery.
Moreover, other breast related diseases such as infections, lesions, and fibrocysts are also expected to contribute towards the growth in early diagnosis.Regional InsightRegional segments of CEA market include North America, Europe, Asia Pacific, Latin America and MEA.
In 2016, North America dominate the regional market pertaining to various key attributes such as increasing patient awareness, rising incidences of cancer, favorable reimbursement policies, and presence of advanced healthcare infrastructure.
According to American Cancer Society in 2017, approximately 1,688,780 new cases of cancer were estimated in the U.S.Asia Pacific region is expected to grow at lucrative rates during the forecast period owing to the factors such as increasing prevalence of cancer in emerging economies such as Brazil, Russia, India, and China, favorable government initiatives, and significant presence of local players will drive the growth of the market in this region.
Global Carcinoembryonic Antigen Market Research Report: Information by Application (Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, and Others), End User (Hospitals and Clinics, Diagnostic Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2027Market HighlightsCarcinoembryogenic antigen (CEA) is a group of glycoproteins which are produced during the fetal developmental stages by gastrointestinal tissues.
CEA is responsible for cell adhesion.
Thus, CEA based diagnostic assays are used for the detection of such cancers and to check the treatment efficiency during the therapeutic period by a physician.In 2017, studies of the NCBI suggested that the global burden of colorectal cancer will increase by 60%, leading to 2.2 million new cancer cases and 1.1 million deaths by 2030.
This will increase the colorectal cancer diagnostic demands, thereby propelling the market growth.Increasing prevalence of cancer, rising healthcare expenditures, and developing diagnostic technologies will boost the global market during the forecast period.
However, risk of infection and hematoma, lack of awareness and medical services in the developing countries will restrain the market growth during the assessment period.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/772Market PlayersSome of key players profiled in the report are Lee BioSolutions, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated., Correlogic Systems, Inc, Genway Biotech, Inc., Abbott., RayBiotech, Inc., Abcam plc., Biocare Medical, LLC, and Biocare Medical, LLC.Regional AnalysisThe Americas account for the largest share in the carcinoembryogenic antigen market.
The Americas mainly include countries like the U.S. and Canada.
